PRAX Stock Summary and Trading Ideas (Praxis Precision Medicines | NASDAQ:PRAX)

Praxis Precision Medicines Inc is a clinical-stage biopharmaceutical company. The firm is engaged in translating genetic insights into the development of therapies for patients affected by central nervous system disorders characterized by a neuronal excitation-inhibition imbalance. The company has generated three clinical-stage product candidates, ulixacaltamide (formerly known as PRAX-944), vormatrigine (formerly known as PRAX-628), and relutrigine (formerly known as PRAX-562), as well as PRAX-020 which has been in-licensed by UCB Biopharma SRL, or UCB.

Praxis Precision Medicines trades on the NASDAQ stock market under the symbol PRAX.

As of January 29, 2026, PRAX stock price climbed to $313.24 with 218,593 million shares trading.

PRAX has a beta of 1.88, meaning it tends to be more sensitive to market movements. PRAX has a correlation of 0.04 to the broad based SPY ETF.

PRAX has a market cap of $8.69 billion. This is considered a Mid Cap stock.

Last quarter Praxis Precision Medicines reported $0 in Revenue and -$3.36 earnings per share. This fell short of revenue expectation by $-59,440 and exceeded earnings estimates by $.11.

In the last 3 years, PRAX traded as high as $326.91 and as low as $11.85.

The top ETF exchange traded funds that PRAX belongs to (by Net Assets): VTI, IWM, XBI, VXF, IWN.

PRAX has outperformed the market in the last year with a price return of +315.7% while the SPY ETF gained +15.5%. PRAX has also outperformed the stock market ETF in the last 3 month and 2 week periods returning +57.1% and +5.0%, respectively, while the SPY returned +0.9% and +0.1%, respectively.

PRAX support price is $297.10 and resistance is $322.74 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that PRAX shares will trade within this expected range on the day.